1
Clinical Trials associated with Anti-CD22 CAR-T cell therapy(Aikangd Biomedical Technology (Suzhou) Co Ltd) / Unknown statusPhase 1/2IIT Application of Humanized Anti-CD22 Antibody in CAR-T Therapy of B Cell Hematological Malignancies
CD19 expression on B cell frequently lost after CD19-targeting CAR-T therapy. In present study, we construct a CD22-targeting chimeric antigen receptor to overcome this issue.
100 Clinical Results associated with Anti-CD22 CAR-T cell therapy(Aikangd Biomedical Technology (Suzhou) Co Ltd)
100 Translational Medicine associated with Anti-CD22 CAR-T cell therapy(Aikangd Biomedical Technology (Suzhou) Co Ltd)
100 Patents (Medical) associated with Anti-CD22 CAR-T cell therapy(Aikangd Biomedical Technology (Suzhou) Co Ltd)
100 Deals associated with Anti-CD22 CAR-T cell therapy(Aikangd Biomedical Technology (Suzhou) Co Ltd)